AIToday
AI in HealthcareTop Companies' AI MovesAI Business & IndustryTop Companies AIPublished: Nov 20, 2026, 06:31 JST

Merck taps Isomorphic Labs for AI oncology drug discovery

Send on LINE
Merck taps Isomorphic Labs for AI oncology drug discovery

3 Key Points

  1. What happened

    Merck announced a research collaboration with Isomorphic Labs to discover small-molecule candidates against an undisclosed oncology target. Isomorphic will run in silico predictions and deliver molecular designs using its IsoDDE engine on Merck's proprietary data; Merck takes responsibility for preclinical and clinical development, manufacturing and commercialization.

  2. Why it matters

    Isomorphic is eligible for research, development, regulatory and commercial milestone payments and tiered royalties on net sales, and can co-fund development for elevated royalties — amounts were not disclosed, so the deal's value remains unquantified.

WHO IT HITSThis deal matters to Merck's oncology research teams and Isomorphic's drug-design scientists, who will apply the IsoDDE engine to Merck's proprietary data sets. It also affects business development teams at other pharma companies weighing similar AI drug-discovery partnerships, though the financial terms remain undisclosed.

Not sure about something? Ask the AI

Questions and answers are published on this page.

Summaries like this, every morning.

Context & Analysis

The Merck deal places Isomorphic Labs' IsoDDE engine at the front of a pharma giant's oncology pipeline, with Isomorphic generating molecular designs from Merck's proprietary data before handing candidates off for preclinical and clinical work. That division of labor — AI design on one side, development and commercialization on the other — mirrors the structure of Isomorphic's earlier partnerships, including its 2024 work with Eli Lilly and Novartis and a January 2026 collaboration with Janssen spanning multiple targets and drug modalities.

The timing is notable: two days before the Merck announcement, Isomorphic raised USD 5 billion in a Series C co-led by Greenoaks and Sequoia Capital, with continued backing from Alphabet. The company said it would use the funding to expand IsoDDE and advance both its own and partnered drug candidates, so the Merck collaboration adds another partnered program to that portfolio. Because the financial terms of the Merck deal were not disclosed, it is not possible to gauge its relative size against those other agreements.

FAQ
What will Isomorphic Labs actually do in the Merck collaboration?
Isomorphic will run in silico predictions and deliver molecular designs using its IsoDDE drug design engine, applied to select proprietary data sets supplied by Merck.
How will Isomorphic Labs be paid?
Isomorphic is eligible for research, development, regulatory and commercial milestone payments and tiered royalties on net sales. It also has an option to co-fund development in return for elevated royalties, though the companies did not disclose amounts.
Who handles development and commercialization after the AI design stage?
Merck takes responsibility for preclinical and clinical development, manufacturing and commercialization of any products resulting from the collaboration.
Top Companies AIRead Original Article
Send on LINE

AI news that matters for your work, delivered every morning.

Pick your industry and the AI tools you use, and get news related to your work every day.

Free · 30 seconds with Google · unsubscribe anytimeWhat is AIToday? →

Ask AI

Ask AI anything about this article. The AI reads this article, earlier AIToday articles, and Wikipedia, and cites its sources. Q&As are published on this page for other readers too.

Questions and answers are published on this page.

Related Articles

Next articlePfizer aims to halve drug R&D timelines with AI, CSO says